AR056418A1 - Derivados de bencimidazol como 5-ht6, 5-ht2a, metodo para la obtencion del compuesto y el uso para la fabricacion de un mediicamento - Google Patents
Derivados de bencimidazol como 5-ht6, 5-ht2a, metodo para la obtencion del compuesto y el uso para la fabricacion de un mediicamentoInfo
- Publication number
- AR056418A1 AR056418A1 ARP060102971A ARP060102971A AR056418A1 AR 056418 A1 AR056418 A1 AR 056418A1 AR P060102971 A ARP060102971 A AR P060102971A AR P060102971 A ARP060102971 A AR P060102971A AR 056418 A1 AR056418 A1 AR 056418A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- hydrogen
- optionally substituted
- independently
- attached
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuestos derivados de bencimidazol, un método para la obtencion de los mismos, composiciones que contienen dichos compuestos y métodos para el uso de los compuestos de la formula (1) para preparar un medicamento. Los compuestos son utiles para tratar enfermedades del SNC como el Parkinson y la ansiedad. Reivindicacion 1: Un compuesto de la formula (1), o una sal farmacéuticamente aceptable de los mismos, en la que: m es un numero 0 a 3; n es 1 o 2; X es: -NRa-; -O-; -S-; -CRbRc-; o -C(O)- ; en los que: Ra es hidrogeno o alquilo; Rb es hidrogeno, fluor o alquilo; Rc es hidrogeno, fluor, alquilo, hidroxi; o alcoxi; o Rb y Rc juntos forman oxo; o Rb y Rc junto con el átomo de carbono al que están unidos pueden formar un anillo de tres a seis eslabones opcionalmente sustituido que contiene opcionalmente un heteroátomo elegido entre O, N y S; Ar es: arilo opcionalmente sustituido; o heteroarilo opcionalmente sustituido; R1 es un grupo de la formula (2); p es un numero de 1 a 4; Y es: -O-; -NRd-; o -CReRf-; en los que Rd, Re y Rf con independencia entre sí son hidrogeno o alquilo; cada R2 con independencia de su aparicion es: halogeno; alquilo; haloalquilo; haloalcoxi; alcoxi; heteroalquilo; ciano; -(CH2)q-S(O)r-Rg; -(CH2)q-C(=O)- NRhRi; -(CH2)q-SO2-NRhRi; -(CH2)q-N(Rj)-C(=O)-Rk, o -(CH2)q-C(=O)-Rk; en los que: q es 0 o 1; r es un numero de 0 a 2; y Rg, Rh, Ri y Rj con independencia entre sí son hidrogeno o alquilo, y Rk es hidrogeno, alquilo, alcoxi o hidroxi; R3 y R4 con independencia entre sí son hidrogeno o alquilo; R5 y R6 con independencia entre sí son hidrogeno o alquilo; y R7 y R8 con independencia entre sí son hidrogeno o alquilo; o R7 y R8 junto con el átomo de nitrogeno al que están unidos pueden formar un anillo de cuatro a siete eslabones opcionalmente sustituido que contiene opcionalmente un heteroátomo adicional elegido entre O, N y S; o uno de R7 y R8 y uno de R5 y R6 unto con los átomos a los que están unidos pueden formar un anillo de cuatro a siete eslabones opcionalmente sustituido que contiene opcionalmente un heteroátomo adicional elegido entre O, N y S; o uno de R7 y R8 junto con Rd y los átomos a los que están unidos pueden formar un anillo de cuatro a siete eslabones opcionalmente sustituido que contiene opcionalmente un heteroátomo adicional elegido entre O, N y S; o uno de R7 y R8 y uno de Re y Rf junto con los átomos a los que están unidos pueden formar un anillo de cuatro a siete eslabones que contiene opcionalmente un heteroátomo adicional elegido entre O, N y S.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69943505P | 2005-07-13 | 2005-07-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR056418A1 true AR056418A1 (es) | 2007-10-10 |
Family
ID=37054633
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060102971A AR056418A1 (es) | 2005-07-13 | 2006-07-11 | Derivados de bencimidazol como 5-ht6, 5-ht2a, metodo para la obtencion del compuesto y el uso para la fabricacion de un mediicamento |
Country Status (16)
Country | Link |
---|---|
US (1) | US7582760B2 (es) |
EP (1) | EP1904483A1 (es) |
JP (1) | JP2009501184A (es) |
KR (1) | KR100983752B1 (es) |
CN (1) | CN101263136A (es) |
AR (1) | AR056418A1 (es) |
AU (1) | AU2006268713A1 (es) |
BR (1) | BRPI0613430A2 (es) |
CA (1) | CA2615007A1 (es) |
IL (1) | IL188486A0 (es) |
MX (1) | MX2008000411A (es) |
NO (1) | NO20080110L (es) |
RU (1) | RU2415138C2 (es) |
TW (1) | TW200738697A (es) |
WO (1) | WO2007006677A1 (es) |
ZA (1) | ZA200800213B (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2301625B1 (en) * | 2004-09-30 | 2017-07-19 | F. Hoffmann-La Roche AG | Compositions and methods for treating cognitive disorders |
US8173813B2 (en) | 2007-03-23 | 2012-05-08 | Neuraxon, Inc. | Quinolone and tetrahydroquinolone and related compounds having NOS inhibitory activity |
RU2009139074A (ru) | 2007-03-23 | 2011-04-27 | Эбботт Гмбх Унд Ко.Кг (De) | Азетидиновые соединения, подходящие для лечения расстройств, чувствительных к модуляции сеотонинового 5-нт6-рецептора |
CN102153538B (zh) * | 2010-02-11 | 2013-12-11 | 山东轩竹医药科技有限公司 | 苯并环衍生物 |
JP6515175B2 (ja) | 2014-07-08 | 2019-05-15 | サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. | 芳香族ヘテロ環誘導体及びその医薬的適用 |
CN108349944B (zh) | 2015-11-06 | 2021-03-30 | 豪夫迈·罗氏有限公司 | 二氢吲哚-2-酮衍生物 |
CN107118161B (zh) * | 2017-05-05 | 2019-12-31 | 湖北工业大学 | 2-正丙基-4-甲基苯并咪唑-6-羧酸的合成方法 |
EP3530651A1 (en) * | 2018-02-21 | 2019-08-28 | Adamed sp. z o.o. | Indole and benzimidazole derivatives as dual 5-ht2a and 5-ht6 receptor antagonists |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2510112A1 (fr) * | 1981-07-24 | 1983-01-28 | Roussel Uclaf | Nouveaux derives du 2-oxo-pyrid-3-yl ou piperidin-3-yl indole, leurs sels, procede de preparation, application a titre de medicaments et compositions les renfermant |
FR2510111A1 (fr) * | 1981-07-24 | 1983-01-28 | Roussel Uclaf | Nouveaux derives du piperidin-3-yl indole, leurs sels, leur procede de preparation, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant |
FR2621586B1 (fr) | 1987-10-08 | 1990-02-02 | Roussel Uclaf | Nouveaux derives de l'azapirodecane, leur procede de preparation et leur application comme medicaments |
TW203049B (es) | 1990-04-13 | 1993-04-01 | Yamanouchi Pharma Co Ltd | |
US5196444A (en) | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
FR2667068B1 (fr) * | 1990-09-26 | 1994-09-09 | Adir | Nouvelles amines alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
US5834587A (en) * | 1996-10-08 | 1998-11-10 | Smithkline Beecham Corporation | G-protein coupled receptor, HLTEX 11 |
WO1999037643A1 (fr) | 1998-01-26 | 1999-07-29 | Yamanouchi Pharmaceutical Co., Ltd. | Nouveaux derives heterocycliques a fusion benzenique ou sels de ceux-ci |
US6310066B1 (en) * | 1998-04-29 | 2001-10-30 | American Home Products Corp. | Antipsychotic indolyl derivatives |
AR015036A1 (es) | 1998-04-29 | 2001-04-11 | American Home Prod | Derivados de indolilo antisicoticos, composicion farmaceutica que los contiene y su uso para la manufactura de un medicamento |
US20020019395A1 (en) | 2000-02-01 | 2002-02-14 | Bing-Yan Zhu | Indalone and benzimidazolone inhibitors of factor Xa |
EP1272483A2 (en) | 2000-03-24 | 2003-01-08 | Millenium Pharmaceuticals, Inc. | OXINDOLE INHIBITORS OF FACTOR Xa |
ES2253370T3 (es) | 2000-04-21 | 2006-06-01 | PHARMACIA & UPJOHN COMPANY LLC | Cabergolina para el tratamiento del sindrome de fibromialgia y de fatiga cronica. |
AR033520A1 (es) | 2000-04-27 | 2003-12-26 | Upjohn Co | (5r)-(metilamino) -5,6-dihidro-4h-imidazo[4,5,1-ij] quinolin-2(1h)-tiona |
US6440096B1 (en) * | 2000-07-14 | 2002-08-27 | Becton, Dickinson And Co. | Microdevice and method of manufacturing a microdevice |
AR031152A1 (es) | 2000-10-31 | 2003-09-10 | Upjohn Co | Tratamientos nuevos para el sindrome de piernas inquietas |
WO2004026837A2 (en) | 2002-09-18 | 2004-04-01 | Eli Lilly And Company | Histamine h3 receptor antagonists, preparaton and therapeutic uses |
CA2502729A1 (en) | 2002-10-25 | 2004-05-06 | Haiyan Wu | Use of heterocyclic amine-type compounds as neuroprotective agents |
ES2298609T3 (es) * | 2002-11-08 | 2008-05-16 | F. Hoffmann-La Roche Ag | Benzoxazinonas sustituidas y usos de las mismas. |
MXPA06000700A (es) * | 2003-07-23 | 2006-04-11 | Wyeth Corp | Compuestos de sulfonildihidroimidazopiridinona como ligandos de 5-hidroxitriptamina-6. |
MXPA06000701A (es) * | 2003-07-23 | 2006-04-11 | Wyeth Corp | Compuestos de sulfonildihidrobencimidazolona como ligandos de 5-hidroxitriptamina-6. |
EP1708713B1 (en) * | 2004-01-16 | 2008-03-12 | F. Hoffmann-la Roche AG | 1-benzyl-5-piperazin-1-yl-3,4 dihydro-1h-quinazolin-2-one derivatives and the respective 1h-benzo(1,2,6)thiadiazine-2,2-dioxide and 1,4-dihydro-benzo(d)(1,3)oxazin-2-one derivatives as modulators of the 5-hydroxytryptamine receptor (5-ht) for the treatment of diseases of the central nervous system |
EP2301625B1 (en) * | 2004-09-30 | 2017-07-19 | F. Hoffmann-La Roche AG | Compositions and methods for treating cognitive disorders |
WO2006066133A2 (en) * | 2004-12-16 | 2006-06-22 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
-
2006
- 2006-07-03 MX MX2008000411A patent/MX2008000411A/es not_active Application Discontinuation
- 2006-07-03 RU RU2008100081/04A patent/RU2415138C2/ru not_active IP Right Cessation
- 2006-07-03 EP EP06777544A patent/EP1904483A1/en not_active Withdrawn
- 2006-07-03 WO PCT/EP2006/063788 patent/WO2007006677A1/en active Application Filing
- 2006-07-03 KR KR1020087000750A patent/KR100983752B1/ko not_active IP Right Cessation
- 2006-07-03 CN CNA2006800333249A patent/CN101263136A/zh active Pending
- 2006-07-03 CA CA002615007A patent/CA2615007A1/en not_active Abandoned
- 2006-07-03 BR BRPI0613430-0A patent/BRPI0613430A2/pt not_active IP Right Cessation
- 2006-07-03 JP JP2008520840A patent/JP2009501184A/ja active Pending
- 2006-07-03 AU AU2006268713A patent/AU2006268713A1/en not_active Abandoned
- 2006-07-10 TW TW095125005A patent/TW200738697A/zh unknown
- 2006-07-11 AR ARP060102971A patent/AR056418A1/es not_active Application Discontinuation
- 2006-07-12 US US11/485,911 patent/US7582760B2/en not_active Expired - Fee Related
-
2007
- 2007-12-27 IL IL188486A patent/IL188486A0/en unknown
-
2008
- 2008-01-08 NO NO20080110A patent/NO20080110L/no not_active Application Discontinuation
- 2008-01-08 ZA ZA200800213A patent/ZA200800213B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
CN101263136A (zh) | 2008-09-10 |
EP1904483A1 (en) | 2008-04-02 |
NO20080110L (no) | 2008-04-11 |
US7582760B2 (en) | 2009-09-01 |
RU2008100081A (ru) | 2009-08-20 |
KR20080019286A (ko) | 2008-03-03 |
TW200738697A (en) | 2007-10-16 |
AU2006268713A1 (en) | 2007-01-18 |
IL188486A0 (en) | 2008-04-13 |
BRPI0613430A2 (pt) | 2011-01-11 |
CA2615007A1 (en) | 2007-01-18 |
MX2008000411A (es) | 2008-03-10 |
WO2007006677A1 (en) | 2007-01-18 |
KR100983752B1 (ko) | 2010-09-24 |
ZA200800213B (en) | 2008-12-31 |
US20070015744A1 (en) | 2007-01-18 |
JP2009501184A (ja) | 2009-01-15 |
RU2415138C2 (ru) | 2011-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR056418A1 (es) | Derivados de bencimidazol como 5-ht6, 5-ht2a, metodo para la obtencion del compuesto y el uso para la fabricacion de un mediicamento | |
AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
ATE556058T1 (de) | 1-(2h)-isochinolonderivat | |
AR072906A1 (es) | Nucleosidos modificados utiles como antivirales | |
AR057769A1 (es) | Pirazolo pirimidinas como inhibidores de map quinasa p38, metodos para utilizarlos y composiciones farmaceuticas | |
AR035774A1 (es) | Derivados benzimidazol y piridilimidazol, un procedimiento para su preparacion, composiciones farmaceuticas y paquetes que los comprenden, el uso de dichos compuestos solos o en combinacion para la manufactura de medicamentos como ligandos para gabaa, y metodo de tratamiento | |
AR077328A1 (es) | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos | |
RU2015148006A (ru) | Дейтерированные нуклеозидные пролекарства, применимые для лечения hcv | |
AR060173A1 (es) | Derivados de piridina y de pirimidina como antagonistas del mglur2, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de trastornos del snc. | |
AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
AR049346A1 (es) | 3-amino-1-arilpropil-indoles como inhibidores de reabsorcion de monoaminas | |
CO6150145A2 (es) | Derivados de aril/heterociclo/cicloalquil/cicloalquil fenil substituidos utiles como agentes inmunosupresores | |
AR080785A1 (es) | Derivados de imidazo[1,2-a]pirimidina ,proceso para prepararlos e intermediarios de dicha sintesis, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de patologias del sistema nervioso central,tales como esquizofrenia y parkinson, entre otros. | |
AR081649A1 (es) | Compuestos heteroarilo nitrogenados | |
AR054890A1 (es) | Derivados de quinolina como agentes antibacterianos | |
AR064414A1 (es) | Derivados de 1-azoniabiciclo[2, 2, 2]octano y 1-azabiciclo[2, 2, 2]oct-3-ilo, un proceso para su preparacion, una composicion farmaceutica que los comprende, procedimiento de obtencion de la misma, su uso en la elaboracion de un medicamento para el tratamiento de epoc y un producto farmaceutico que | |
AR068376A1 (es) | Amidas heterociclicas utiles para inhibir la via hedgehog. | |
NO20080871L (no) | N-(Heteroaryl)-1-heteroarylalkyl-1 H-indol-2-karboksamidderivater, fremstilling og terapeutisk anvendelse derav | |
ES2612921T3 (es) | Compuestos de difluorolactama como agonistas selectivos del receptor EP4 para su uso en el tratamiento de enfermedades y afecciones mediadas por EP4 | |
AR065891A1 (es) | Derivados de piridina y pirimidina como antagonistas del mglur2 | |
AR039988A1 (es) | Derivados de benzoxazina como moduladores de 5-ht6 y usos de los mismos | |
PE20061362A1 (es) | Derivados de tetrahidronaftalina, procedimientos para su preparacion y su uso como inhibidor de la inflamacion | |
AR063636A1 (es) | Derivados de indol y de benzofurano-2-carboxamida | |
NI201000134A (es) | Nuevos derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |